Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key SCLC patient populations covering 171 countries and more than 99% of…
Clarivate Epidemiology's coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key SCLC patient populations covering 171 countries and more than 99% of…
Clarivate Epidemiology’s coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China…
Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China…